Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients

Diabet. Med. 27, 289–294 (2010)

[1]  R. Freeman,et al.  Diabetic Neuropathy , 2010, Diabetes Care.

[2]  F. Zaccardi,et al.  Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy , 2009, Diabetes Care.

[3]  A. Sjølie,et al.  Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients , 2009, Diabetologia.

[4]  B. Sahan,et al.  Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. , 2008, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[5]  M. Nybo,et al.  Osteoprotegerin released from the vascular wall by heparin mainly derives from vascular smooth muscle cells. , 2008, Atherosclerosis.

[6]  M. Nybo,et al.  The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. , 2008, European journal of endocrinology.

[7]  C. Thompson,et al.  Increased Matrix Metalloproteinase 2 Activity in the Human Internal Mammary Artery Is Associated with Ageing, Hypertension, Diabetes and Kidney Dysfunction , 2008, Journal of Vascular Research.

[8]  A. Sjølie,et al.  Proliferative retinopathy and proteinuria predict mortality rate in type 1 diabetic patients from Fyn County, Denmark , 2008, Diabetologia.

[9]  S. Khalifé,et al.  Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population , 2006, Clinical endocrinology.

[10]  A. Tuğrul,et al.  The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. , 2005, Diabetes research and clinical practice.

[11]  P. Olesen,et al.  Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α , 2005, Diabetologia.

[12]  W. Jeffcoate.  Vascular calcification and osteolysis in diabetic neuropathy—is RANK-L the missing link? , 2004, Diabetologia.

[13]  L. Rasmussen,et al.  Aortic collagen alterations in human diabetes mellitus. Changes in basement membrane collagen content and in the susceptibility of total collagen to cyanogen bromide solubilisation , 1993, Diabetologia.

[14]  A. Green,et al.  Epidemiological studies of diabetes mellitus in Denmark , 1980, Diabetologia.

[15]  W. Fraser,et al.  Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. , 2003, Clinical chemistry.

[16]  P. Poulsen,et al.  Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. , 2003, European journal of endocrinology.

[17]  William Maloney,et al.  Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.

[18]  S. Cummings,et al.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. , 2001, The Journal of clinical endocrinology and metabolism.

[19]  L. Hofbauer,et al.  The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1 , 2000 .

[20]  D. Hu,et al.  Use of the Semmes-Weinstein monofilament in the strong heart study. Risk factors for clinical neuropathy. , 1999, Diabetes care.

[21]  S. Groth,et al.  Chromium-51-EDTA clearance in adults with a single-plasma sample. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[23]  E Mervaala,et al.  Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[24]  Sjølie Ak.  Ocular complications in insulin treated diabetes mellitus. An epidemiological study. , 1985 .

[25]  A. Sjølie.  Ocular complications in insulin treated diabetes mellitus. An epidemiological study. , 1985, Acta ophthalmologica. Supplement.

[26]  J. Gundersen.  Segmental measurements of systolic blood pressure in the extremities including the thumb and the great toe. , 1972, Acta chirurgica Scandinavica. Supplementum.

[27]  S. Carter,et al.  Digital Systolic Pressures in the Lower Limb in Arterial Disease , 1971, Circulation.